Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00054197 · ClinicalTrials.gov registry record · Phase 3
Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 3 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00054197: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.
NCT00054197 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00054197, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether polyglutamate paclitaxel is more effective than gemcitabine or vinorelbine in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of polyglutamate paclitaxel with that of gemcitabine or vinorelbine in treating patients who have stage IIIB, stage IV, or recurrent non-small cell lung cancer.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG vinorelbine tartrate
- DRUG paclitaxel poliglumex
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00054197
The ClinicalTrials.gov registry entry for NCT00054197 describes a study currently listed as terminated, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00054197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00054197 about?
NCT00054197 is a clinical study titled "Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether polyglutamate paclitaxel is more effective than gemcitabine or vinorelbine in treating non-small...
What is the current status of trial NCT00054197?
This trial is currently terminated. It is a Phase 3 study. The study started on 2003-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00054197?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), vinorelbine tartrate (DRUG), paclitaxel poliglumex (DRUG).
Who is sponsoring clinical trial NCT00054197?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.